Results 11 to 20 of about 173,723 (245)

Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson’s disease: insights from the PPMI cohort [PDF]

Journal of Translational Medicine
Background Long-term levodopa treatment for Parkinson’s disease (PD) is often complicated by motor fluctuations and dyskinesia. Predictive biomarkers for these debilitating side effects are currently lacking, hindering personalized treatment.
Jieshan Chi, Rui Yang, Piao Zhang, Siming Rong, Mengfei Cai, Yuhu Zhang   +5 more
doaj   +2 more sources

From medications to surgery: advances in the treatment of motor complications in Parkinson’s disease [PDF]

Drugs in Context, 2019
Motor complications are responsible for the large burden of disability and poor quality of life in Parkinson’s disease (PD). The pulsatile nature of stimulation with oral dopaminergic therapies due to relatively short pharmacokinetic profiles and ...
Kanae Jennifer Nagao, Neepa J Patel
doaj   +2 more sources

Medical Management and Prevention of Motor Complications in Parkinson's Disease [PDF]

Neurotherapeutics, 2020
, Stephen Aradi, Hauser Robert A
exaly   +2 more sources

Discrepancies in symptom concerns and burden from the perspectives of parkinson's disease patients, caregivers, and physicians [PDF]

Frontiers in Neurology
BackgroundDiscrepancies in symptom concerns and the perceived burden among individuals with Parkinson's disease (PD), their caregivers, and their physicians can hinder effective care.ObjectivesWe investigated differences in symptom recognition and ...
Shohei Okusa, Shohei Okusa, Shohei Okusa, Toshiki Tezuka, Toshiki Tezuka, Toshiki Tezuka, Tomonori Nukariya, Tomonori Nukariya, Tomonori Nukariya, Yoshihiro Nihei, Yoshihiro Nihei, Yoshihiro Nihei, Jin Nakahara, Jin Nakahara, Jin Nakahara, Morinobu Seki, Morinobu Seki, Morinobu Seki   +17 more
doaj   +2 more sources

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease

Brain Sciences, 2021
Background: In the advanced stages of Parkinson’s disease (APD), complex forms of dyskinesia may severely impair the patient’s quality of life. Objective: In the present study, we aimed to analyze the evolution under LCIG therapy of the most important ...
József Attila Szász, Viorelia Adelina Constantin, Károly Orbán-Kis, Ligia Ariana Bancu, Marius Ciorba, István Mihály, Előd Ernő Nagy, Róbert Máté Szász, Krisztina Kelemen, Mihaela Adriana Simu, Szabolcs Szatmári   +10 more
doaj   +1 more source

Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Years [PDF]

Movement Disorders Clinical Practice
Michele Hu, Tanja Zerenner, Huw Morris   +2 more
exaly   +2 more sources

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

Frontiers in Neurology, 2021
Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories.
Robert A. Hauser, Ryan R. Walsh, Rajesh Pahwa, Dustin Chernick, Andrea E. Formella   +4 more
doaj   +1 more source

Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease

Frontiers in Neurology, 2021
Objective: This study aimed to evaluate the direct anti-dyskinesia effect of deep brain stimulation (DBS) of subthalamic nucleus (STN) on levodopa-induced on-dyskinesia in Parkinson's disease (PD) patients during the early period after surgery without ...
Jiping Li, Shanshan Mei, Xiaofei Jia, Yuqing Zhang   +3 more
doaj   +1 more source

Predictors of motor complications in early Parkinson's disease: A prospective cohort study [PDF]

Movement Disorders, 2019
Michele Hu, Yoav Ben-Shlomo, Fahd Baig   +2 more
exaly   +2 more sources

Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?

Clinical and Translational Neuroscience, 2021
Parkinson's disease (PD) is a chronic neurologic disease that has a great impact on the patient’s quality of life. The natural course of the disease is characterized by an insidious onset of symptoms, such as rest tremor, shuffling gait, bradykinesia ...
Oleg S. Levin, Olga V. Iakovleva, Irina I. Coloman, Anastasia V. Kuzmina   +3 more
doaj   +1 more source